Development of Class IIa Bacteriocins as Therapeutic Agents
Author(s) -
Christopher T. Lohans,
John C. Vederas
Publication year - 2011
Publication title -
international journal of microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.696
H-Index - 40
eISSN - 1687-9198
pISSN - 1687-918X
DOI - 10.1155/2012/386410
Subject(s) - bacteriocin , antimicrobial , antimicrobial peptides , in vivo , biology , cytotoxicity , potency , computational biology , microbiology and biotechnology , pharmacology , chemistry , in vitro , biochemistry
Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom